


 Christoph C Zielinski<sup>1,2</sup>

**To cite:** Zielinski CC. How I treat cancer special issue. *ESMO Open* 2019;4:e000514. doi:10.1136/esmoopen-2019-000514

Received 13 March 2019  
Accepted 14 March 2019

Within the 3 years of its existence, *ESMO Open – Cancer Horizons* has so far published a total of 330 articles dealing with all possible aspects of cancer and cancer care. These have included papers in the following areas: epidemiological studies<sup>1 2</sup>; access to cancer care<sup>3–7</sup>; the advent of biologicals and their broad use in the clinic<sup>8 9</sup>; various aspects of magnitude of clinical benefit achieved by the use of certain drugs<sup>10 11</sup>; biological considerations on the regulation of tumour growth<sup>12 13</sup> and propagation<sup>14–16</sup>; clinical cutting-edge papers on the treatment of cancer in selected unfamiliar situations<sup>1 17–21</sup>; new treatment options either registered by the European Medicines Agency (which *ESMO Open* regularly publishes in its ‘EMA Corner’<sup>22</sup>) or a broader understanding of existing compounds<sup>23–28</sup> in an abundance of various cancers<sup>29–35</sup> and quality of life issues of cancer patients.<sup>3 36–42</sup> These patient-oriented publications were complemented by aspects concerning the oncological profession.<sup>4 43</sup> Further, a more profound understanding of challenging side effects was addressed in several articles.<sup>44–50</sup> Thus, *ESMO Open – Cancer Horizons* has established itself as a reliable source of information on the very many aspects of cancer and cancer care published within it. This is corroborated by the high levels of engagement with the journal’s content. Since launch there have been 581 000 page views from 325 000 users around the world. In 2018, usage from the Americas exceeded that from Europe for the first time (125 000 views vs 108 000 views).

The European Society for Medical Oncology (ESMO) importantly and regularly publishes and updates guidelines on the treatment of cancers.<sup>51–54</sup> This series of guidelines has become very much rightly truly iconic in the oncological community. The current special issue of *ESMO Open – Cancer Horizons* is the result of a request we have sent out to key opinion leaders in various fields of cancer in which we have asked them to give a very succinct opinion on how they would treat cancer in a very special and circumscribed situation related to predefined diagnosis. Thus, we have intended to present the oncological community with an endeavour which would encompass a series of ESMO’s attempts including the generation of

guidelines,<sup>51</sup> the results of the Magnitude of Clinical Benefit<sup>10 11 36</sup> and personal considerations of key opinion leaders.<sup>55–58</sup> We hope that these very short and succinct summaries will help you in your everyday care of patients with cancer who give the true meaning to all of our endeavours.

**Funding** The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

**Competing interests** Consultancies and Speaker’s Honoraria: Roche, Novartis, BMS, MSD, Imugene, Ariad, Pfizer, Merrimack, Merck KGaA, Fibrogen, AstraZeneca, Tesaro, Gilead, Servier, Shire, Eli Lilly, Athenex

**Patient consent for publication** Not required.

**Provenance and peer review** Not commissioned; internally peer reviewed.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, any changes made are indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

## REFERENCES

- Funakoshi T, Horimatsu T, Nakamura M, *et al*. Chemotherapy in cancer patients undergoing haemodialysis: a nationwide study in Japan. *ESMO Open* 2018;3:e000301.
- Girard N, Cozzone D, de Leotoing L, *et al*. Extra cost of brain metastases (BM) in patients with non-squamous non-small cell lung cancer (NSCLC): a French National Hospital database analysis. *ESMO Open* 2018;3:e000414.
- Antonella S, Flavia V, Daniela T, *et al*. The ‘Charter of Rights for Family Caregivers’. The role and importance of the caregiver: an Italian proposal. *ESMO Open* 2017;2:e000256.
- Hojgaard L, Lowenberg B, Selby P, *et al*. The European Cancer Patient’s Bill of Rights, update and implementation 2016. *ESMO Open* 2016;1:e000127.
- Hui D, Cherny NI, Wu J, *et al*. Indicators of integration at ESMO designated centres of integrated oncology and palliative care. *ESMO Open* 2018;3:e000372.
- Prager GW, Braga S, Bystricky B, *et al*. Global cancer control: responding to the growing burden, rising costs and inequalities in access. *ESMO Open* 2018;3:e000285.
- Saletti P, Sanna P, Gabutti L, *et al*. Choosing wisely in oncology: necessity and obstacles. *ESMO Open* 2018;3:e000382.
- Wolff-Holz E, Garcia Burgos J, Giuliani R, *et al*. Preparing for the incoming wave of biosimilars in oncology. *ESMO Open* 2018;3:e000420.
- Taberner J, Vyas M, Giuliani R, *et al*. Biosimilars: a position paper of the European Society for medical oncology, with particular reference to oncology prescribers. *ESMO Open* 2017;1:e000142.

© Author (s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. Published by BMJ on behalf of the European Society for Medical Oncology.

<sup>1</sup>Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria

<sup>2</sup>Central European Cancer Center, Vienna, Austria

### Correspondence to

Professor Christoph C Zielinski; christoph.zielinski@meduniwien.ac.at

10. Kiesewetter B, Raderer M, Prager GW, *et al.* The European Society for Medical Oncology 'Magnitude of Clinical Benefit Scale' field-tested in infrequent tumour entities: an extended analysis of its feasibility at the Medical University of Vienna. *ESMO Open* 2017;2:e000166.
11. Dafni U, Karlis D, Pedeli X, *et al.* Detailed statistical assessment of the characteristics of the ESMO magnitude of clinical benefit scale (ESMO-MCBS) threshold rules. *ESMO Open* 2017;2:e000216.
12. Merlano MC, Granetto C, Fea E, *et al.* Heterogeneity of colon cancer: from bench to bedside. *ESMO Open* 2017;2:e000218.
13. Connell CM, Doherty GJ. Activating HER2 mutations as emerging targets in multiple solid cancers. *ESMO Open* 2017;2:e000279.
14. Saraiva DP, Guadalupe Cabral M, Jacinto A, *et al.* How many diseases is triple negative breast cancer: the protagonism of the immune microenvironment. *ESMO Open* 2017;2:e000208.
15. Sherwood JL, Brown H, Rettino A, *et al.* Key differences between 13 KRAS mutation detection technologies and their relevance for clinical practice. *ESMO Open* 2017;2:e000235.
16. Wolf Y, Samuels Y. Cancer research in the era of immunogenomics. *ESMO Open* 2018;3:e000475.
17. Martinelli E, Troiani T, Sforza V, *et al.* Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case. *ESMO Open* 2018;3:e000299.
18. Glitza IC, Rohlfms M, Guha-Thakurta N, *et al.* Retrospective review of metastatic melanoma patients with leptomeningeal disease treated with intrathecal interleukin-2. *ESMO Open* 2018;3:e000283.
19. Torgeson A, Garrido-Laguna I, Tao R, *et al.* Value of surgical resection and timing of therapy in patients with pancreatic cancer at high risk for positive margins. *ESMO Open* 2018;3:e000282.
20. Peeters M, Forget F, Karthaus M, *et al.* Exploratory pooled analysis evaluating the effect of sequence of biological therapies on overall survival in patients with RAS wild-type metastatic colorectal carcinoma. *ESMO Open* 2018;3:e000297.
21. Poggio F, Lambertini M, Bighin C, *et al.* Management of young women with early breast cancer. *ESMO Open* 2018;3(Suppl 1):e000458.
22. Stanel SC, Sjöberg J, Salmonson T, *et al.* European Medicines Agency approval summary: Zaltrap for the treatment of patients with oxaliplatin-resistant metastatic colorectal cancer. *ESMO Open* 2017;2:e000190.
23. Granier C, De Guillebon E, Blanc C, *et al.* Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer. *ESMO Open* 2017;2:e000213.
24. Moilanen T, Mustanoja S, Karihtala P, *et al.* Retrospective analysis of HER2 therapy interruption in patients responding to the treatment in metastatic HER2+ breast cancer. *ESMO Open* 2017;2:e000202.
25. Grob J-J, Mortier L, D'Hondt L, *et al.* Safety and immunogenicity of MAGE-A3 cancer immunotherapeutic with dacarbazine in patients with MAGE-A3-positive metastatic cutaneous melanoma: an open phase I/II study with a first assessment of a predictive gene signature. *ESMO Open* 2017;2:e000203.
26. Oizumi S, Sugawara S, Minato K, *et al.* Updated survival outcomes of NEJ005/TCOG0902: a randomised phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations. *ESMO Open* 2018;3:e000313.
27. Mishima S, Kawazoe A, Matsumoto H, *et al.* Efficacy and safety of ramucirumab-containing chemotherapy in patients with pretreated metastatic gastric neuroendocrine carcinoma. *ESMO Open* 2018;3:e000443.
28. Dummer R, Michielin O, Nägeli MC, *et al.* Phase I, open-label study of pasireotide in patients with BRAF- wild type and NRAS -wild type, unresectable and/or metastatic melanoma. *ESMO Open* 2018;3:e000388.
29. Solinas C, Gombos A, Latifyan S, *et al.* Targeting immune checkpoints in breast cancer: an update of early results. *ESMO Open* 2017;2:e000255.
30. Taberner J, Van Cutsem E, Ohtsu A, *et al.* QTWiST analysis of the recourse trial of trifluridine/tipiracil in metastatic colorectal cancer. *ESMO Open* 2017;2:e000284.
31. Moore KN, Bauer TM, Falchook GS, *et al.* Phase I study of the investigational oral mTORC1/2 inhibitor sapanisertib (TAK-228): tolerability and food effects of a milled formulation in patients with advanced solid tumours. *ESMO Open* 2018;3:e000291.
32. Fiedler W, Cresta S, Schulze-Bergkamen H, *et al.* Phase I study of tomuzotuximab, a glycoengineered therapeutic antibody against the epidermal growth factor receptor, in patients with advanced carcinomas. *ESMO Open* 2018;3:e000303.
33. Ueno T, Saji S, Masuda N, *et al.* Impact of clinical response to neoadjuvant endocrine therapy on patient outcomes: a follow-up study of JFMC34-0601 multicentre prospective neoadjuvant endocrine trial. *ESMO Open* 2018;3:e000314.
34. Okusaka T, Ikeda M. Immunotherapy for hepatocellular carcinoma: current status and future perspectives. *ESMO Open* 2018;3(Suppl 1):e000455.
35. Yoo SH, Keam B, Kim M, *et al.* Low-dose nivolumab can be effective in non-small cell lung cancer: alternative option for financial toxicity. *ESMO Open* 2018;3:e000332.
36. Henon C, Lissa D, Paoletti X, *et al.* Patient-reported tolerability of adverse events in phase 1 trials. *ESMO Open* 2017;2:e000148.
37. Si O, Socinski MA, Gadgeel S, *et al.* Patient-reported outcomes in a phase II, North American study of alectinib in patients with ALK-positive, crizotinib-resistant, non-small cell lung cancer. *ESMO Open* 2018;3:e000364.
38. Van Cutsem E, Falcone A, Garcia-Carbonero R, *et al.* Proxies of quality of life in metastatic colorectal cancer: analyses in the recourse trial. *ESMO Open* 2017;2:e000261.
39. Wood R, Mitra D, de Courcy J, *et al.* Patient-reported pain severity, pain interference and health status in HR+/HER2- advanced/metastatic breast cancer. *ESMO Open* 2017;2:e000227.
40. Saloustros E, Stark DP, Michailidou K, *et al.* The care of adolescents and young adults with cancer: results of the ESMO/SIOPE survey. *ESMO Open* 2017;2:e000252.
41. Cheng S, Qureshi M, Pullenayegum E, *et al.* Do patients with reduced or excellent performance status derive the same clinical benefit from novel systemic cancer therapies? A systematic review and meta-analysis. *ESMO Open* 2017;2:e000225.
42. Vardy JL, Dhillon HM, Pond GR, *et al.* Prognostic indices of inflammatory markers, cognitive function and fatigue for survival in patients with localised colorectal cancer. *ESMO Open* 2018;3:e000302.
43. Patsou ED, Alexias GD, Anagnostopoulos FG, *et al.* Effects of physical activity on depressive symptoms during breast cancer survivorship: a meta-analysis of randomised control trials. *ESMO Open* 2017;2:e000271.
44. Yang H, Deng Q, Qiu Y, *et al.* Erlotinib intercalating pemetrexed/cisplatin versus erlotinib alone in Chinese patients with brain metastases from lung adenocarcinoma: a prospective, non-randomised, concurrent controlled trial (NCT01578668). *ESMO Open* 2016;2(Suppl 1):e000112.
45. Ramos-Esquivel A, van der Laet A, Rojas-Vigott R, *et al.* Anti-PD-1/anti-PD-L1 immunotherapy versus docetaxel for previously treated advanced non-small cell lung cancer: a systematic review and meta-analysis of randomised clinical trials. *ESMO Open* 2017;2:e000236.
46. Kastrisios M, Kostadima F-L, Kefas A, *et al.* Nivolumab-induced hypothyroidism and selective pituitary insufficiency in a patient with lung adenocarcinoma: a case report and review of the literature. *ESMO Open* 2017;2:e000217.
47. Doherty GJ, Duckworth AM, Davies SE, *et al.* Severe steroid-resistant anti-PD1 T-cell checkpoint inhibitor-induced hepatotoxicity driven by biliary injury. *ESMO Open* 2017;2:e000268.
48. Merle P, Camus P, Aberger A, *et al.* Safety and efficacy of intra-arterial hepatic chemotherapy with doxorubicin-loaded nanoparticles in hepatocellular carcinoma. *ESMO Open* 2017;2:e000238.
49. Varricchi G, Galdiero MR, Marone G, *et al.* Cardiotoxicity of immune checkpoint inhibitors. *ESMO Open* 2017;2:e000247.
50. Geukes Foppen MH, Rozeman EA, van Wilpe S, *et al.* Immune checkpoint inhibition-related colitis: symptoms, endoscopic features, histology and response to management. *ESMO Open* 2018;3:e000278.
51. Pallari E, Fox AW, Lewison G. Differential research impact in cancer practice guidelines' evidence base: lessons from ESMO, NICE and SIGN. *ESMO Open* 2018;3:e000258.
52. Pedrazzoli P, Silvestris N, Santoro A, *et al.* Management of patients with end-stage renal disease undergoing chemotherapy: recommendations of the Associazione Italiana di Oncologia MEDICA (AIOM) and the Società Italiana di Nefrologia (sin). *ESMO Open* 2017;2:e000167.
53. López RI, Castro JL, Cedeño H, *et al.* Consensus on management of metastatic colorectal cancer in Central America and the Caribbean: San José, Costa Rica, August 2016. *ESMO Open* 2018;3:e000315.
54. Ay C, Kamphuisen PW, Agnelli G. Antithrombotic therapy for prophylaxis and treatment of venous thromboembolism in patients with cancer: review of the literature on current practice and emerging options. *ESMO Open* 2017;2:e000188.
55. Rodriguez-Vida A, Hutson TE, Bellmunt J, *et al.* New treatment options for metastatic renal cell carcinoma. *ESMO Open* 2017;2:e000185.



56. Popovic LS, Matovina-Brko G, Popovic M. Checkpoint inhibitors in the treatment of urological malignancies. *ESMO Open* 2017;2:e000165.
57. Salati M, Di Emidio K, Tarantino V, *et al.* Second-line treatments: moving towards an opportunity to improve survival in advanced gastric cancer? *ESMO Open* 2017;2:e000206.
58. Loong HH, Wong K-H, Tse T. Controversies and consensus of neoadjuvant chemotherapy in soft-tissue sarcomas. *ESMO Open* 2018;3(Suppl 1):e000293.